Analyst Price Targets — MPLT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 31, 2026 11:19 am | Ami Fadia | Needham | $43.00 | $12.60 | StreetInsider | MapLight Therapeutics (MPLT) PT Lowered to $43 at Needham |
| August 14, 2026 12:42 pm | Sumant Kulkarni | Canaccord Genuity | $21.00 | $11.63 | TheFly | MapLight Therapeutics price target lowered to $21 from $24 at Canaccord |
| August 14, 2026 12:27 pm | — | Raymond James | $31.00 | $11.59 | TheFly | MapLight Therapeutics price target lowered to $31 from $35 at Raymond James |
| August 10, 2026 10:25 am | — | UBS | $13.00 | $12.17 | TheFly | MapLight Therapeutics downgraded to Neutral from Buy at UBS |
| July 28, 2026 1:17 pm | Adam Vogel | Craig-Hallum | $25.00 | $10.21 | TheFly | MapLight Therapeutics price target lowered to $25 from $40 at Craig-Hallum |
| July 28, 2026 11:13 am | Sumant Kulkami | Canaccord Genuity | $24.00 | $9.91 | StreetInsider | MapLight Therapeutics (MPLT) PT Lowered to $24 at Canaccord |
| July 28, 2026 10:50 am | — | Morgan Stanley | $21.00 | $9.91 | TheFly | MapLight downgraded to Equal Weight from Overweight at Morgan Stanley |
| July 28, 2026 10:02 am | Raghuram Selvaraju | H.C. Wainwright | $26.00 | $9.91 | TheFly | MapLight Therapeutics price target lowered to $26 from $45 at H.C. Wainwright |
| July 27, 2026 8:04 pm | Rudy Li | Wolfe Research | $30.00 | $9.91 | StreetInsider | MapLight Therapeutics (MPLT) PT Lowered to $30 at Wolfe Research |
| July 24, 2026 10:48 am | Sumant Kulkarni | Canaccord Genuity | $43.00 | $35.23 | TheFly | MapLight Therapeutics price target raised to $43 from $35 at Canaccord |
Latest News for MPLT
Reported positive results from the potentially registrational Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia, supporting advancement into a Phase 3 ZEPHYR-2 trial Continued advancement of ML-007C-MA in ADP, with enrollment ongoing in the Phase 2 VISTA trial and topline results expected in the second half of 2027 Reported Phase 2 IRIS results for ML-004 in autism spectrum disorder, with clinically meaningful…
SAN FRANCISCO and BOSTON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, announced today that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement…
LOS ANGELES, Aug. 3, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors ofMapLight Therapeutics, Inc. ("MapLight" or "the Company") (NASDAQ: MPLT) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and/or misleading statements…
Shares of Maplight Therapeutics, Inc. (NASDAQ: MPLT - Get Free Report) rose 18.2% on Wednesday after an insider bought additional shares in the company. The stock traded as high as $14.49 and last traded at $14.5480. Approximately 378,003 shares were traded during mid-day trading, a decline of 6% from the average daily volume of 402,503 shares.
ADAR1 Capital Management LLC acquired a new stake in shares of Maplight Therapeutics, Inc. (NASDAQ: MPLT) during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 374,909 shares of the company's stock, valued at approximately $7,622,000. ADAR1 Capital Management LLC owned
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for MPLT.
Senate Trading
No Senate trades found for MPLT.
U.S. House Trading
No House trades found for MPLT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.